Since the beginning of the campaign, Argentina received a total of 42,801,930 vaccines.
–
A total of 7 million second doses of vaccines against the coronavirus will be applied during August, to complete the inoculation schedules, as announced this Friday by President Alberto Fernández, while A shipment of 200,000 doses of the Convidecia vaccine, developed by the Chinese laboratory Cansino Biologics INC., arrived in the country at dawn.
“In August we will apply more than 7 million second doses. In addition, we will continue to apply the first doses to adolescents between 12 and 17 years old who have been prioritized,” he said. Alberto Fernndez announcing a plan of “sustained and progressive openings” to recover activities “responsibly and with care”.
In this context, the President affirmed that the objective to this month “is to increase the percentage of second doses, prioritizing people over 50 years of ageespecially those who have more time since the first dose. “
The Cansino vaccine requires a single dose for complete immunization.
–
“The more we vaccinate and take care of ourselves, the more we will be able to sustain these achievements and the more we will be able to advance in sustained and progressive openings,” Fernández said in a message from Casa Rosada.
Also, anticipate that this month “again millions of vaccines will arrive in the country” and he recalled that “the combination that facilitates advancing in the second doses also begins.”
“We are entering a new stage; each time there is less. We are going to live the life we want responsibly again,” said the president.
For her part, the Minister of Health, Carla Vizzotti anticipated that, after the arrival of 200 thousand doses of the Cansino vaccine this Friday, there are “perspectives for the month of August of 200 thousand more” and explained that “they are working so that can immediately incorporate the protocol of combination of schemes, as happened with Moderna, to speed up the second dose as quickly as possible ”.
Carla Vizzotti anticipated that, after the arrival of 200 thousand doses of the Cansino vaccine this Friday, there are prospects for the month of August of 200 thousand ms
–
He explained that “another role that the Cansino vaccine may have is that it is a single dose to have a complete vaccination” and in that we are “working with the technical areas of the jurisdictions, so that, in those populations that have difficult access and difficulties, the vaccination schedule can be completed ”.
“We are working a lot since the challenge was generated that Argentina can produce the Sputnik V vaccine, in everything that are controls, technology transfer, formulation and quality controls and We are in the last stage of the administrative steps so that by having the final Ok from Gamaleya and Anmat, between Monday and Tuesday, we can receive, not only the doses of component 2, but also the lots of component 1 that are already in, ”he remarked.
He also stated that “the expectation is to be able to sign the contract with the Pfizer laboratory and to be able to start receiving the first doses at the end of September or early October, in addition to now completing the vaccination of prioritized adolescents, and to think about vaccinating the between 12 and 17 years old ”.
The objective for this month “is to increase the percentage of second doses, prioritizing people over 50 years of age, especially those who have more time since the first dose,” informed the President.
–
Meanwhile, a shipment of 200,000 doses of the Convidecia vaccine, developed by the Chinese laboratory Cansino Biologics INC., Arrived at Ezeiza airport at dawn this Friday, on a flight from the Qatar Airways airline, within the framework of the Plan Strategic Vaccination of the national Government against the coronavirus.
The shipment with the 200,000 doses of this serum of single application, arrived at 2.20 this Friday to Ezeiza, on flight QR8157 from Qatar, it was officially reported.
As explained, It is the “first game of a contract that contemplates the shipment of 5.4 million of doses in the course of this year “, as Minister Vizzotti anticipated at a press conference days ago.
Since the beginning of the campaign, Argentina received a total of 42,801,930 vaccines, of which 14,768,000 correspond to Sinopharm; 11,868,830 to Sputnik V (9,375,670 from component 1 and 2,493,160 from component 2); 9,941,100 to those of AstraZeneca and Oxford whose active principle was produced in Argentina; 3,500,000 to Moderna; 1,944,000 to AstraZeneca through the WHO COVAX mechanism and 580,000 to AstraZeneca-Covishield, and now 200,000 from Cansino.
Alberto Fernndez pointed out that the first doses will continue to be applied to adolescents between 12 and 17 years old who have been prioritized
–
According to data from the Public Vaccination Monitor, Until this Friday, 38,572,954 doses of vaccines had been distributed throughout the national territory, while 33,825,576 were applied.
Of this total, 25,840,629 people were inoculated with the first dose and 7,984,947 have the complete vaccination scheme.
The Convidecia vaccine, of which a first batch of 200,000 doses arrived in the country this Friday, is an immunizer developed by the Chinese laboratory Cansino Biologics Inc that is applied in a single dose. and that, after 28 days, it was more than 65% effective against symptomatic Covid-19 and more than 90% against severe disease.
The Cansino vaccine needs a temperature of 2 to 8 degrees Celsius for its preservation, which implies an advantage for logistics.
–
According to information from its developers, 14 days after the application Convidecia was 68.83% effective in preventing all symptomatic Covid-19 diseases and 95.47% effective in preventing serious disease.
Meanwhile, after 28 days, it was 65.28% effective against all symptomatic diseases and 90.07% effective in preventing serious disease.
The phase III clinical trial of Ad5-nCoV has vaccinated more than 40,000 volunteers at 78 clinical trial centers in five countries on three continents.
???? “Our priority for the month of August is to increase the percentage of second doses, prioritizing people over 50 years of age, especially those who have been longer since the first dose.” President @alferdez in the announcement from Casa Rosada. pic.twitter.com/SG045QmJSi
Alberto Fernndez Press (@alferdezprensa) August 6, 2021
–
It is a vaccine that uses human adenovirus 5 (which causes the common cold) as a non-replicative viral vector to transport the spike protein of the coronavirus.
When the vaccine enters the body, adenovirus 5 does not replicate so it does not cause disease, and once it enters cells, the gene is transcribed to express protein S, which acts as an antigen that triggers the host’s immune response. .
The vaccine needs a temperature of 2 to 8 degrees Celsius for its preservation, which implies an advantage for logistics.
Chile was the first South American country to approve the use of this vaccine, after Mexico, Pakistan, China and Hungary.
– .
